DAS28-CRP Remission Data

Discover Strength of Balance


Sustained clinical remission in MTX-IR patients (p<0.001 vs. MTX at Week 24)2

MTX-IR patients achieving clinical remission

Sustained DAS28-CRP <2.6 remission through Week 52 in MTX-IR patients2

Adapted from Combe B, et al. 20212
*p<0.001 vs. MTX + placebo. Nominal P value.
†52-week data were not controlled for multiplicity.


Clinical remission in biologic-IR patients (p<0.001 vs. csDMARD)3

Biologic-IR patients achieving clinical remission

DAS28-CRP <2.6 remission continued through Week 24 in
biologic-IR patients3

Adapted from Genovese MC, et al. 20193
*p<0.001 vs. csDMARD + placebo.

Discover Strength of Balance

ACR Data


Radiographic Progression

Head-to-Head vs. Adalimumab

JYSELECA is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).1 JYSELECA may be used as monotherapy or in combination with methotrexate (MTX).1

References: 1. JYSELECA SPC. Available at: www.medicines.org.uk / www.medicines.ie. Last accessed: October 2022. 2. Combe B, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219214. 3. Genovese MC, et al. JAMA 2019;322 (4):315–325. 4. Westhovens R, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-219213. 5. Combe B, et al. Arthritis Rheumatol 2021;73(suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-filgotinib-treatment-in-an-ongoing-long-term-extension-trial-of-ra-patients-with-inadequate-response-to-mtx-initially-treated-with-filgotinib-or-adalimumab-during-th/. Last accessed: October 2022. 6. Buch MH, et al. Arthritis Rheumatol 2021;73 (suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-ongoing-filgotinib-ra-long-term-extension-trial-of-biologic-dmard-inadequate-responders-initially-on-filgotinib-or-placebo-in-a-phase-3-trial/. Last accessed: October 2022. 7. Data on file - Gilead Sciences Ltd - INF-UK-20-04. 8. Data on file - Gilead Sciences Ltd - INF-UK-20-06. 9. Data on file - Gilead Sciences Ltd - INF-UK-20-11.